GLP-1 & Incretin Science

What the Meta-Analysis Established

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

He and colleagues published a systematic review and meta-analysis in JAMA Internal Medicine in 2022 examining the association of GLP-1 receptor agonist use with risk of gallbladder and biliary diseases. The pooled analysis that turned scattered trial observations into an estimate.

Key facts

Study
He 2022, JAMA Intern Med (PMID 35344001)
Design
Systematic review and meta-analysis
Outcome
Gallbladder and biliary diseases
Why pooled
Events too infrequent in single trials
Mechanism identified
CCK suppression (Rehfeld 2018)
Tirzepatide-specific
Zeng 2023 (PMID 37908750)

Why individual trials could not answer this

Gallbladder events occur in a small percentage of participants. A trial powered to detect a difference in weight reduction is not powered to detect a difference in an outcome affecting a few per cent, so individual trials produce numbers too small to interpret, a handful of events in each arm, consistent with almost anything.

What pooling achieves

Combining events across many randomised trials produces enough of them to estimate a difference with usable precision, while retaining randomisation. That is the key advantage over an observational cohort: confounding by indication does not arise, because assignment was random within each contributing trial.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why this signal was noticed at all

Because it appeared consistently. A scattering of gallbladder events across many trials of the same drug class, in the same direction, is the pattern that prompts a formal pooled analysis. Isolated events in one trial would not have.

The tirzepatide-specific question

Zeng and colleagues addressed pancreatitis and gallbladder or biliary disease with tirzepatide specifically in a systematic review and meta-analysis in Frontiers in Endocrinology in 2023. Compound-specific analyses matter because this class has already proven non-uniform. The oral contraceptive interaction is tirzepatide-specific and not shared by the pure GLP-1 agonists.

How to read a pooled safety estimate

As a relative measure attached to an absolute baseline. A relative increase in an infrequent event remains an infrequent event, and a relative figure quoted without the underlying rate conveys almost nothing about magnitude. This is the most common way safety meta-analyses are misreported.

What it does not describe

Anything supplied on this site. These analyses pool randomised trials of licensed and investigational medicines administered under clinical supervision. No research material is a GLP-1 receptor agonist or is covered by any of this evidence.

Frequently asked questions

Why was a meta-analysis needed?

Gallbladder events are too infrequent for a single weight-loss trial to detect a difference. Pooling produces enough events to estimate one.

Is pooled randomised data better than a cohort?

For this question, yes on one axis. Randomisation within each trial removes confounding by indication, which cohort studies cannot.

How should a relative increase be read?

Against the absolute baseline rate. A relative increase in an infrequent event is still infrequent, and the relative figure alone conveys little.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.